Programmed Death 1 Blockade With Nivolumab in Patients With Recurrent Malignant Pleural Mesothelioma

Journal of Thoracic Oncology

Volumn 13, Issue 10, 2018, Pages 1569-1576

  Quispel Janssen, Josine ^a   van der Noort, Vincent ^a   de Vries, Jeltje F ^a   Zimmerman, Marion ^a   Lalezari, Ferry ^a   Thunnissen, Erik ^b   Monkhorst, Kim ^a   Schouten, Robert ^a   Schunselaar, Laurel ^a   Disselhorst, Maria ^a   Klomp, Houke ^a   Hartemink, Koen ^a   Burgers, Sjaak ^a   Buikhuisen, Wieneke ^a   Baas, Paul ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Checkpoint inhibitor; Immunotherapy; Mesothelioma; Nivolumab; Programmed death ligand 1

Indexed keywords

AMIODARONE; C REACTIVE PROTEIN; LACTATE DEHYDROGENASE; NIVOLUMAB; PROGRAMMED DEATH 1 RECEPTOR; IMMUNOLOGICAL ANTINEOPLASTIC AGENT;

ACUTE KIDNEY FAILURE; ADULT; AGED; ALLERGIC REACTION; ARTICLE; ATRIAL FIBRILLATION; BIOCHEMISTRY; CLINICAL ARTICLE; COLITIS; CONTROLLED STUDY; DISEASE CONTROL RATE; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FEVER; HUMAN; HUMAN CELL; INFUSION RELATED REACTION; LEUKOCYTE COUNT; LIVER BIOCHEMISTRY; LYMPHOCYTE; MALE; MALIGNANT PLEURA EFFUSION; NAUSEA; NEUTROPHIL LYMPHOCYTE RATIO; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERICARDIAL EFFUSION; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; PRURITUS; SIDE EFFECT; TREATMENT RESPONSE; VOMITING; CLINICAL TRIAL; LUNG TUMOR; MESOTHELIOMA; MIDDLE AGED; PATHOLOGY; PLEURA TUMOR; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MESOTHELIOMA; MIDDLE AGED; NIVOLUMAB; PLEURAL NEOPLASMS; PROGRESSION-FREE SURVIVAL; PROSPECTIVE STUDIES;

EID: 85050396674     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1016/j.jtho.2018.05.038     Document Type: Article

References (32)

1. LaDou, J., Castleman, B., Frank, A., et al. The case for a global ban on asbestos. Environ Health Perspect 118 (2010), 897–901.
2. Vogelzang, N.J., Rusthoven, J.J., Symanowski, J., et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21 (2003), 2636–2644.
3. Buikhuisen, W.A., Hiddinga, B.I., Baas, P., van Meerbeeck, J.P., Second line therapy in malignant pleural mesothelioma: a systematic review. Lung Cancer 89 (2015), 223–231.
4. Keir, M.E., Liang, S.C., Guleria, I., et al. Tissue expression of PD-L1 mediates peripheral T cell tolerance. J Exp Med 203 (2006), 883–895.
5. Hamid, O., Robert, C., Daud, A., et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 369 (2013), 134–144.
6. Brahmer, J., Reckamp, K.L., Baas, P., et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 373 (2015), 123–135.
7. Borghaei, H., Paz-Ares, L., Horn, L., et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373 (2015), 1627–1639.
8. Motzer, R.J., Escudier, B., McDermott, D.F., et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 373 (2015), 1803–1813.
9. Mansfield, A.S., Roden, A.C., Peikert, T., et al. B7-H1 expression in malignant pleural mesothelioma is associated with sarcomatoid histology and poor prognosis. J Thorac Oncol 9 (2014), 1036–1040.
10. Cedres, S., Ponce-Aix, S., Zugazagoitia, J., et al. Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM). PloS ONE, 10, 2015, e0121071.
11. Khanna, S., Thomas, A., Abate-Daga, D., et al. Malignant mesothelioma effusions are infiltrated by CD3+ T cells highly expressing PD-L1 and the PD-L1+ tumor cells within these effusions are susceptible to ADCC by the anti-PD-L1 antibody avelumab. J Thorac Oncol 11 (2016), 1993–2005.
12. Combaz-Lair, C., Galateau-Salle, F., McLeer-Florin, A., et al. Immune biomarkers PD-1/PD-L1 and TLR3 in malignant pleural mesotheliomas. Human Pathol 52 (2016), 9–18.
13. Herbst, R.S., Soria, J.C., Kowanetz, M., et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515 (2014), 563–567.
14. Brahmer, J.R., PD-1-targeted immunotherapy: recent clinical findings. Clin Adv Hematol Oncol 10 (2012), 674–675.
15. Byrne, M.J., Nowak, A.K., Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann Oncol 15 (2004), 257–260.
16. Wolchok, J.D., Hoos, A., O'Day, S., et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 15 (2009), 7412–7420.
17. Zucali, P.A., Simonelli, M., Michetti, G., et al. Second-line chemotherapy in malignant pleural mesothelioma: results of a retrospective multicenter survey. Lung Cancer 75 (2012), 360–367.
18. Alley, E.W., Lopez, J., Santoro, A., et al. Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial. Lancet Oncol 18 (2017), 623–630.
19. Kindler, H., Karrison, T., Tan, Y.H.C., et al. Phase II trial of pembrolizumab in patients with malignant mesothelioma (mm): interim analysis. J Thorac Oncol 12 (2017), S293–S294.
20. Herbst, R.S., Baas, P., Kim, D.W., et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non–small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 387 (2016), 1540–1550.
21. Hassan, R., Thomas, A., Patel, M.R., et al. Avelumab (MSB0010718C; anti-PD-L1) in patients with advanced unresectable mesothelioma from the JAVELIN solid tumor phase Ib trial: safety, clinical activity, and PD-L1 expression. J Clin Oncol, 34(15 suppl), 2016, 8503.
22. Chiou, V.L., Burotto, M., Pseudoprogression and immune-related response in solid tumors. J Clin Oncol 33 (2015), 3541–3543.
23. Champiat, S., Dercle, L., Ammari, S., et al. Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti-PD-1/PD-L1. Clin Cancer Res 23 (2017), 1920–1928.
24. Kato, S., Goodman, A., Walavalkar, V., Barkauskas, D.A., Sharabi, A., Kurzrock, R., Hyperprogressors after immunotherapy: analysis of genomic alterations associated with accelerated growth rate. Clin Cancer Res 23 (2017), 4242–4250.
25. Hirsch, F.R., McElhinny, A., Stanforth, D., et al. PD-L1 immunohistochemistry assays for lung cancer: results from phase 1 of the Blueprint PD-L1 IHC assay comparison project. J Thorac Oncol 12 (2017), 208–222.
26. Thunnissen, E., Allen, T.C., Adam, J., et al. Immunohistochemistry of pulmonary biomarkers: a perspective from members of the Pulmonary Pathology Society. Arch Pathol Lab Med 142 (2018), 408–419.
27. Pardoll, D.M., The blockade of immune checkpoints in cancer immunotherapy. Nature Rev Cancer 12 (2012), 252–264.
28. Taube, J.M., Anders, R.A., Young, G.D., et al. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med, 4, 2012, 127ra137.
29. Taube, J.M., Klein, A., Brahmer, J.R., et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res 20 (2014), 5064–5074.
30. Blank, C.U., Haanen, J.B., Ribas, A., Schumacher, T.N., Cancer immunology. The “cancer immunogram.”. Science 352 (2016), 658–660.
31. Nakagawa, M., Terashima, T., D'Yachkova, Y., Bondy, G.P., Hogg, J.C., van Eeden, S.F., Glucocorticoid-induced granulocytosis: contribution of marrow release and demargination of intravascular granulocytes. Circulation 98 (1998), 2307–2313.
32. Kao, S.C., Pavlakis, N., Harvie, R., et al. High blood neutrophil-to-lymphocyte ratio is an indicator of poor prognosis in malignant mesothelioma patients undergoing systemic therapy. Clin Cancer Res 16 (2010), 5805–5813.